INTRODUCTION
============

Paroxysmal dyskinesia is a rare and heterogeneous group of movement disorders characterized by recurrent episodes of involuntary dystonia, chorea, athetosis, or their combination. It is usually categorized into three subgroups based on the triggers: paroxysmal kinesigenic dyskinesia (PKD), paroxysmal nonkinesigenic dyskinesia (PNKD), and paroxysmal exercise-induced dyskinesia (PED).[@B1][@B2] Hypnogenic paroxysmal dyskinesia, formerly considered to be the fourth type of paroxysmal dyskinesia, is now known to be a form of nocturnal frontal lobe epilepsy.[@B3] PKD, the most common type of paroxysmal movement disorder, shows brief recurrent attacks precipitated when initiating voluntary movements. The duration of an attack is usually shorter than for other types, commonly lasting for less than 1 min. The age at onset is usually between 7 and 15 years, and patients show fair responses to anticonvulsants such as carbamazepine or oxcarbazepine.[@B4][@B5] Attacks in patients with PNKD usually have a longer duration (up to several hours) and are triggered by alcohol, coffee, or emotional stress.[@B6] Symptoms usually begin before the age of 20 years and treatment responses are worse than in PKD. Symptoms of PED are triggered by sustained exercise, with a mean age at onset of 5 years, and anticonvulsant therapy does not seem to be very useful.[@B4] All three types of dyskinesias are often associated with other neurologic disorders such as infantile seizures, other types of epilepsy, migraine, writer\'s cramp, ataxia, or tremor.[@B4][@B6][@B7][@B8][@B9][@B10][@B11][@B12]

Since the myofibrillogenesis regulator 1 gene (*MR-1*, OMIM 609023) was first identified as the cause of PNKD in 2004,[@B13] protein-rich transmembrane protein 2 gene (*PRRT2*, OMIM 614386) for PKD and solute carrier family 2, member 1 gene (*SLC2A1*, OMIM 138140) for PED have been found.[@B14][@B15] Although recent studies have found that the phenotype and genotype overlap as well as various manifestations within the subtypes and phenotype heterogeneity over the paroxysmal dyskinesias,[@B16][@B17][@B18] there have been few large integrated studies, especially those involving the pediatric population. We therefore aimed to determine the clinical and genetic features of pediatric patients with paroxysmal dyskinesias and identify the clinical and genetic heterogeneities.

METHODS
=======

Study approval and registration of patients
-------------------------------------------

The study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1101-110-353 for DNA preparation and IRB No. 1708-148-879 for genetic tests and the retrospective review of medical records). All of the patients or their legal representatives provided written informed consent to participate in the present study.

We enrolled 55 patients with paroxysmal dyskinesia at Seoul National University Children\'s Hospital from 2013 to 2016. The diagnosis was based on clinical criteria from previous reports.[@B4][@B6][@B19] Organic causes were excluded based on clinical, laboratory, and imaging findings.

Sequencing for *PRRT2*, *SLC2A1*, and *MR-1*
--------------------------------------------

Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA Blood Midi Kit according to the manufacturer\'s instructions (Qiagen, Valencia, CA, USA). Polymerase chain reaction (PCR) amplification was performed with each specific primer pair designed by the authors. The PCR conditions used were 95℃ for 3 min, followed by 35 cycles of 95℃ for 30 s, 57℃ for 30 s, and 72℃ for 40 s, with a final extension at 72℃ for 5 min. Sanger sequencing reactions were run on an ABI 3730XL DNA Analyzer (Applied Biosystems Inc., Carlsbad, CA, USA) to identify *PRRT2*, *SLC2A1*, and *MR-1*. After *PRRT2* sequencing was performed for all patients, *SLC2A1* sequencing was performed for the remaining *PRRT2*-negative patients. Thereafter, Sanger sequencing of *MR-1* was performed for mutation-negative patients with PNKD. The pathogenicity of variants was evaluated according to the standards and guidelines of the American College of Medical Genetics and Genomics (ACMG).[@B20]

Data collection and analysis
----------------------------

We reviewed the medical records of all patients to obtain information on age, sex, symptoms, age at onset, family history, combined medical conditions, medication, and responsiveness to treatment. We classified patients into three groups according to clinical criteria[@B4][@B6][@B19] and described the clinical features of all of the patients. Treatment responses were classified into the following four categories: symptom-free, markedly improved (75--99% reduction of symptoms), minimally improved (25--75% reduction of symptoms), and no change (0--24%) or aggravated. We compared the clinical features between patients with PKD and PNKD, and furthermore analyzed those of PKD patients with and without *PRRT2* mutations.

Statistical analyses were conducted using the IBM SPSS statistics version 22.0 software suite (IBM Corp., Armonk, NY, USA). Student\'s *t* test was applied to continuous variables and the Pearson chi-square test applied to categorical variables. The range of probability values for statistical significance was set at *p*\<0.05.

RESULTS
=======

Clinical characteristics
------------------------

Among the 55 cases in this study, 40 (72.7%) were categorized as PKD, 14 (25.5%) as PNKD, and only 1 (1.8%) as PED. Seventeen cases (30.9%) were familial: 13 with paroxysmal dyskinesia and 4 with benign familial infantile seizures (BFIS). Fifteen cases from 13 families were categorized as PKD, 1 as PNKD, and 1 as PED. Males comprised 38 (69.1%) of the patients. The follow-up duration was 3.20±3.27 years (mean±SD, range=0.2--14 years), and the age at symptom onset was 8.80±4.53 years (range=0.4--15 years). Brain MRI was performed in 49 patients (89.1%), with the findings being unremarkable except for 1 case of venous angioma and 1 of dysgenesis of the corpus callosum.

The clinical characteristics of PKD and PNKD are compared in [Table 1](#T1){ref-type="table"}. The most common symptom in both groups was dystonia. Patients with PKD were more likely to have a family history (*p*=0.043) and shorter symptom attacks (*p*=0.001). Patients with PNKD presented their first symptom at an earlier age (*p*=0.001). Epilepsy other than BFIS were more commonly found in patients with PNKD (*p*=0.001), while BFIS were observed only in patients with PKD. Comorbidities such as mild intellectual disability, tic disorder, and attention deficit hyperactivity disorder (ADHD) were observed in 6 patients with PKD (15%) and 5 with PNKD (35.7%). Fourteen patients with PKD (35.0%) had other additional triggering factors such as tension, emotional stress, cold exposure, and infections. Antiepileptic drugs (including oxcarbazepine) were administered to 37 and 13 patients in the PKD and PNKD groups, respectively, and a symptom-free state was achieved in 22 (64.7%) and 4 (30.8%) patients, respectively.

Genetic analysis of *PRRT2*, *SLC2A1*, and *MR-1*
-------------------------------------------------

Pathogenic variants in *PRRT2* and *SLC2A1* were identified in 18 and 2 patients, respectively, while no *MR-1* mutations were found. The phenotypes and genotypes of all mutation-positive patients are described in [Table 2](#T2){ref-type="table"}. All *PRRT2*-positive patients presented as PKD alone, whereas two patients with *SLC2A1* mutations had PNKD and PED. All of the *PRRT2* mutations were frameshift mutations, with the exception of a single missense mutation. The c.649dupC variant in *PRRT2* was the most common (9/17, 52.9%). Additionally, two novel mutations in *PRRT2* were identified: c.387dupA and c.914_931delinsAGACGCT, both of which were pathogenic based on the ACMG standards and guidelines. The 2 patients with *SLC2A1* mutations comprised one with a splice-site mutation and one with a missense mutation: c.276-1G\>A and c.997C\>T.

Comparison between PKD patients with and without *PRRT2* mutations
------------------------------------------------------------------

We compared the clinical features between PKD patients with and without *PRRT2* mutations ([Table 3](#T3){ref-type="table"}). Familial cases were more common in PKD patients with *PRRT2* mutations (*p*=0.050). Dyskinesia of both sides of limbs manifested in 61.1% of the *PRRT2*-positive patients, with the remainder showing unilateral dyskinesia (*p*=0.009). No significant differences were observed in the main presenting symptom or combined medical problems, although *PRRT2*-positive PKD patients were more likely to have a history of BFIS (*p*=0.155), and *PRRT2*-negative PKD patients were more likely to have other medical problems such as tic disorder, ADHD, or intellectual disability (*p*=0.197). Both groups showed good treatment responses: 94.1% and 82.3% in *PRRT2*-positive and *PRRT2*-negative PKD patients, respectively.

DISCUSSION
==========

Paroxysmal dyskinesia can be classified into three groups based on the triggers, and this classification facilitates the diagnosis. However, clinical and genetic heterogeneity (even within the same phenotype) as well as phenotype--genotype overlap among the three groups reportedly make it difficult to establish an etiologic diagnosis in some cases. Additionally, the pathophysiologies of PKD, PNKD, and PED associated with the roles of *PRRT2*, *SLC2A1*, and *MR-1* have not been elucidated completely, even though recent studies on synaptopathies, transportopathies, and channelopathies have been reported.[@B21][@B22]

The clinical and genetic characteristics were investigated in this large cohort of pediatric patients with paroxysmal dyskinesia. As expected, PKD was the most common type and showed a male predominance with a mean age at onset of 10.1 years. Dystonia was the most common symptom in these patients, with short duration of less than 1 min, and 64.7% achieved a symptom-free state with oxcarbazepine or carbamazepine alone. Five patients with PKD (12.5%) had a history of BFIS, four of whom carried *PRRT2* mutations. Six *PRRT2* mutations were identified in 9 of the 13 tested families (69.2%) and in 8 patients of the 25 tested sporadic cases (32.0%) of PKD. The most common mutation was c.649dupC, which accounted for 50% of *PRRT2*-positive PKD patients. This mutation was not carried in sporadic cases in another Korean cohort, whereas we identified it in 62.5% of patients with sporadic cases of *PRRT2*-positive PKD.[@B23] This represents a hotspot mutation in patients with sporadic and familial cases of PKD worldwide.[@B16][@B24] Consistent with previous studies, 35% of all of the patients with PKD (about 22% of *PRRT2*-positive PKD patients) had other additional triggering factors besides initiating voluntary movements, including tension, emotional stress, cold exposure, and infections. The treatment response did not differ significantly between the *PRRT2*-positive and *PRRT2*-negative groups, which is consistent with previous studies and might be due to some pathomechanisms being shared between different genetic defects.[@B23][@B25]

The second most common type in this study was PNKD, and all but one of the cases were sporadic. Only one of the patients with PNKD had variants in the three genes: a pathogenic variant in *SLC2A1*. Most studies of PNKD reported to date have involved familial cases, and furthermore there have been no sporadic cases with *MR-1* mutations reported.[@B26][@B27][@B28] A recent study indicated that the mean age at symptom onset among patients with *MR-1*-negative familial PNKD was over 12 years.[@B26] Our patients with PNKD showed their first symptom at a mean age of 5.4 years. Moreover, their attacks tended to be shorter, with a duration of only a few seconds in about half of our patients, compared with this exceeding 10 min in previous reports.[@B26][@B27][@B28] Although our patients were clinically classified into the PNKD type based on the triggers, they might represent another group within pediatric paroxysmal dyskinesia rather than simply *MR-1*-negative PNKD. As expected, other comorbidities such as epilepsy, tic disorder, ADHD, or cognitive disability were commonly reported in our PNKD patients.[@B26] Together these findings indicate that neurologic comorbidities such as neurodevelopmental delay or epilepsy other than BFIS are observed in mutation-negative patients with PKD or PNKD, and suggest the presence of other genetic mutations such as a channelopathy in *SCN8A* or *KCNMA1*. Further investigations that include genetic testing for these two genes might be needed in the remaining mutation-negative patients.

Phenotype--genotype overlap was identified in the present study, although there were no *PRRT2*-positive patients presenting with PNKD or PED. One patient with a splicesite mutation (c.276-1G\>A in *SLC2A1*) showed PNKD, and another patient carrying the c.997C\>T variant had PED. Both of these patients exhibited developmental delay and epilepsy. It is known that *SLC2A1* mutations are usually found in PED patients, but the PNKD phenotype has also been reported.[@B16] Our *SLC2A1*-positive PNKD patient experienced dystonic attacks that typically lasted 10--15 min, occurred frequently during the day, and were triggered by emotional stress, sustained exercise, and fatigue. He was diagnosed with glucose transporter 1 (GLUT1) deficiency after a low glucose level was measured in the cerebrospinal fluid (37 mg/dL; ratio of cerebrospinal fluid to serum glucose of 0.3), and showed marked improvement of symptoms after consuming a ketogenic diet. The other patient with the c.997C\>T variant in *SLC2A1* was a 13-year-old boy who suffered from intermittent dystonia in his lower extremities triggered by intense exercise or rapidly walking 700--800 meters. We diagnosed GLUT1 deficiency and started him on diet therapy. Although *SLC2A1* mutations accounted for a small portion in our cohort, the elucidation of genetic causes is very important for initiating early treatments.

Most previous investigators have reported the clinical features of PKD patients as well as the genetic analysis of *PRRT2*, with mutations reportedly appearing in from 18.5% to 65% of cases.[@B23][@B24][@B25] One recent study found *PRRT2*, *SLC2A1*, and *MR-1* mutations in 35%, 10%, and 2% of 145 patients with paroxysmal dyskinesia, respectively, indicating clinical and genetic heterogeneity, as well as phenotype--genotype overlap.[@B16] There have been no genetic or clinical studies involving a large cohort of patients with pediatric paroxysmal dyskinesia. We screened for the top-3 causative genes in 55 patients from 53 families with pediatric paroxysmal dyskinesia, although sequencing for MR-1 was only performed in patients with PNKD. Only one of the PRRT2-negative and *SLC2A1*-negative patients with paroxysmal dyskinesia had an autosomal dominant family history in our present cohort that had PKD with epilepsy, and therefore a lower possibility of any *MR-1* mutations. *PRRT2*, *SLC2A1*, and *MR-1* mutations were identified in 18 (32.7%), 2 (3.6%), and 0 of the present cohort with pediatric paroxysmal dyskinesia patients, respectively.

In conclusion, the present study has expanded the clinical and genetic spectrum of pediatric paroxysmal dyskinesia. Additionally, both the heterogeneity and phenotype--genotype overlap of paroxysmal dyskinesia have been summarized. In some cases it is difficult to make a diagnosis based on clinical features alone. This means that broader genetic testing including for at least three genes should be performed in patients with pediatric paroxysmal dyskinesia to aid the search for treatable cases.
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###### Demographic data of and clinical manifestation in patients with PKD and PNKD

![](jcn-14-492-i001)

                                         PKD (*n*=40)   PNKD (*n*=14)   *p*-value
  -------------------------------------- -------------- --------------- -----------
  Sex (male:female)                      31:9           6:8             0.023^\*^
  Family history (*n*, %)                15 (37.5)      1 (7.1)         0.043^\*^
  Onset age (years, mean±SD)             10.1±3.77      5.4±4.95        0.001^\*^
  Presenting symptoms (*n*, %)                                          0.819
   Dystonia only                         25 (62.5)      7 (50.0)        
   Choreoathetosis only                  10 (25.0)      4 (28.6)        
   Dystonia+choreoathetosis              2 (5.0)        1 (7.1)         
   Other                                 3 (7.5)        2 (14.3)        
  Duration of symptom (*n*, %)                                          0.001^\*^
   \<1 minutes                           38 (95.0)      7 (50.0)        
   ≥1 minutes                            2 (5.0)        7 (50.0)        
  Localization (*n*, %)                                                 0.066
   Unilateral                            17 (42.5)      4 (28.6)        
   Bilateral                             13 (32.5)      3 (21.4)        
   Alternating                           5 (12.5)       6 (42.9)        
   Unknown                               5 (12.5)       1 (7.1)         
  Facial involvement (*n*, %)            1 (2.5)        1 (7.1)         0.473
  Prodromal symptom (*n*, %)             14 (35.0)      3 (21.4)        0.507
  Other aggravating factors (*n*, %)     14 (35.0)      6 (46.2)        0.522
  Combined medical problem^†^ (*n*, %)   15 (37.5)      9 (64.3)        0.120
   Febrile seizures                      4 (10.0)       0 (0.0)         0.565
   Benign infantile convulsion           5 (12.5)       0 (0.0)         0.311
   Other epilepsy                        1 (2.5)        6 (42.9)        0.001^\*^
   Others                                6 (15.0)       5 (35.7)        0.129
  Treatment (*n*, %)                                                    NA
   Medication given                      37 (92.5)      13 (92.9)       
   Mean treatment duration (mean±SD)     4.9±3.28       2.6±2.39        
  Symptom reduction (*n*, %)                                            0.202
   Symptom free                          22 (64.7)      4 (30.8)        
   Markedly improved                     8 (23.5)       6 (46.2)        
   Minimally improved                    2 (5.9)        1 (7.7)         
   No change or aggravated               2 (5.9)        2 (15.4)        

^\*^*p*\<0.05, ^†^Some patients have two or more comorbidities.

NA: not available, PKD: paroxysmal kinesigenic dyskinesia, PNKD: paroxysmal nonkinesigenic dyskinesia.

###### Clinical features of patients with mutation in *PRRT2* and *SLC2A1*

![](jcn-14-492-i002)

  No.     Age/sex   Phenotype   Family history   Gene       Nucleotide change        Amino acid change     Inheritance   Reference
  ------- --------- ----------- ---------------- ---------- ------------------------ --------------------- ------------- -----------
  1^\*^   M/22      PKD         Yes              *PRRT2*    c.629delC                p.Pro210Glnfs^\*^19   NA            CD128941
  2^\*^   M/24      PKD         Yes              *PRRT2*    c.629delC                p.Pro210Glnfs^\*^19   NA            CD128941
  3       M/12      PKD         Yes              *PRRT2*    c.629delC                p.Pro210Glnfs^\*^19   NA            CD128941
  4       F/31      PKD         Yes              *PRRT2*    c.649delC                p.R217Efs^\*^12       Paternal      CI120173
  5       F/10      PKD         No               *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  6       F/15      PKD         No               *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  7       F/7       PKD         No               *PRRT2*    c.649dupC                p.R217Pfs^\*^8        *De novo*     CI120173
  8       M/24      PKD         Yes              *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  9       F/17      PKD         No               *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  10      M/19      PKD         Yes              *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  11      M/18      PKD         Yes              *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  12      F/16      PKD         No               *PRRT2*    c.649dupC                p.R217Pfs^\*^8        NA            CI120173
  13      M/14      PKD         Yes              *PRRT2*    c.649dupC                p.R217Pfs^\*^8        Paternal      CI120173
  14      M/14      PKD         No               *PRRT2*    c.649delC                p.R217Efs^\*^12       *De novo*     CD126062
  15      M/7       PKD         No               *PRRT2*    c.649delC                p.R217Efs^\*^12       NA            CD126062
  16      M/27      PKD         Yes              *PRRT2*    c.913G\>A                p.Gly305Arg           Maternal      CM120147
  17      F/21      PKD         No               *PRRT2*    c.914_931delinsAGACGCT   p.Gly305Glufs^\*^31   NA            Novel
  18      M/21      PKD         Yes              *PRRT2*    c.387dupA                p.Ala130Serfs^\*^4    Paternal      Novel
  19      M/16      PNKD        No               *SLC2A1*   c.276-1G\>A              splicing site         *De novo*     CS1515747
  20      M/13      PED         Yes              *SLC2A1*   c.997C\>T                p.R333W               Maternal      CM002410

^\*^Two siblings from the same family had no parental history, although both parents were not tested.

NA: not available, PED: paroxysmal exercise-induced dyskinesia, PKD: paroxysmal kinesigenic dyskinesia, PNKD: paroxysmal nonkinesigenic dyskinesia.

###### Comparison of *PRRT2*-positive and -negative paroxysmal kinesigenic dyskinesia

![](jcn-14-492-i003)

                                          Mutation-positive (*n*=18)   Mutation-negative (*n*=22)   *p*-value
  --------------------------------------- ---------------------------- ---------------------------- -----------
  Sex (male:female)                       11:7                         20:2                         0.053
  Age of symptom onset (years, mean±SD)   10.6±2.80                    10.2±3.97                    0.713
  Family history (*n*, %)                 10 (55.6)                    5 (22.7)                     0.050
  Presenting symptoms (*n*, %)                                                                      0.961
   Dystonia only                          11 (61.1)                    14 (63.6)                    
   Chorea only                            5 (27.8)                     5 (22.7)                     
   Dystonia+chorea                        1 (5.6)                      1 (4.5)                      
   Others                                 1 (5.6)                      2 (9.1)                      
  Localization (*n*, %)                                                                             0.009^\*^
   Unilateral                             4 (22.2)                     13 (59.1)                    
   Bilateral                              6 (33.3)                     7 (31.8)                     
   Alternating                            5 (27.8)                     0 (0.0)                      
   Unknown                                3 (16.7)                     2 (9.1)                      
  Facial involvement (*n*, %)             1 (5.6)                      0 (0.0)                      0.405
  Prodromal symptoms (*n*, %)             8 (44.4)                     6 (27.3)                     0.327
  Other aggravating factors (*n*, %)      5 (27.8)                     9 (40.9)                     0.510
  Combined medical problem^†^ (*n*, %)    8 (44.4)                     7 (31.8)                     0.517
   Febrile seizure                        3 (16.7)                     1 (4.5)                      0.310
   Benign infantile convulsions           4 (23.5)                     1 (4.5)                      0.155
   Other epilepsies                       0 (0.0)                      1 (4.5)                      1.000
   Others                                 1 (5.9)                      5 (22.7)                     0.197
  Response to treatment^‡^ (*n*, %)                                                                 0.358
   Treatment given                        17 (100.0)                   17 (100.0)                   
   Symptom-free                           13 (76.5)                    9 (52.9)                     
   Markedly improved                      3 (17.6)                     5 (29.4)                     
   Minimally improved                     1 (5.9)                      1 (5.9)                      
   Aggravated                             0 (0.0)                      2 (11.8)                     

^\*^*p*\<0.05, ^†^Some patients have two or more comorbidities, ^‡^All patients in the *PRRT2*-positive group received oxcarbazepine only. In the *PRRT2*-negative negative group, 18 patients took oxcarbazepine only, other 2 recived oxcarbazepine plus valproate.

[^1]: ^\*^These authors contributed equally to this work.
